Roohi Ismail-Khan, MD

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  University of South Florida, Tampa, FL - Medical Oncology

RESIDENCY:
          •  University of South Florida, Tampa, FL - Internal Medicine

MEDICAL SCHOOL:
          •  St. George's University of Medicine, Grenada, WI - MD

• Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromata. J Clin Oncol. 2013 May;31(17):2128-2135. Pubmedid: 23650416.


• Donovan KA, Boyington AR, Ismail-Khan R, Wyman JF. Urinary symptoms in breast cancer: a systematic review. Cancer. 2012 Mar;118(3):582-593. Pubmedid: 21751193. Pmcid: PMC3193898.


• Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Mar;30(5):533-538. Pubmedid: 22231041. Pmcid: PMC3295555.


• Bardhan P, Bui MM, Minton S, Loftus L, Carter WB, Laronga C, Ismail-Khan R. HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature. Ann Clin Lab Sci. 2012;42(2):135-139. Pubmedid: 22585608.


• Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Aug;104(12):1828-1835. Pubmedid: 21559012. Pmcid: PMC3111195.


• Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010 Jul;17(3):173-176. Pubmedid: 20664514.


• Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.


• Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007;39(7-8):1318-1328. Pubmedid: 17600754. Pmcid: PMC3167070.


• Ismail-Khan R, Robinson L, Williams CC J, Garrett C, Bepler G, Simon G. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006 Oct;13(4):255-263. Pubmedid: 17075562.


• Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul;13(3):211-217. Pubmedid: 16885917.

Dr. Roohi Ismail-Khan is a medical oncologist specializing in breast cancer in The Center for Women’s Oncology at Moffitt Cancer Center.  She finds the field of breast medical oncology an exciting one as advances in treatment and the delivery of targeted therapies improve prognosis for everyone, including patients with advanced stage disease.  The knowledge that breast cancer is not just one disease, but many, just as every patient is unique, also sets a new standard in personalized care.

As a mother of four children herself, Dr. Ismail-Khan is aware of the psychosocial needs of women diagnosed with breast cancer, including the consequences of treatment affecting feelings about their femininity and the impact on the family dynamic.

Dr. Ismail-Khan’s research interests include reducing or eliminating long-term side effects of chemotherapy to improve quality of life.  She is also focused on triple negative breast cancer; an aggressive disease that responds well to therapy, but often recurs and spreads.  The question why is a challenge that medical oncologists must answer. Dr. Ismail-Khan was selected to present her research on triple negative breast cancer at the prestigious ASCO/ACCR “Methods in Clinical Research” Conference in Colorado.

Dr. Ismail-Khan speaks several languages, including Spanish, Urdu and Hindi.